# A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients

> **NCT06199557** · PHASE1,PHASE2 · RECRUITING · sponsor: **Haukeland University Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, Adult
- Myelodysplastic Syndromes, Adult

## Interventions

- **DRUG:** Hydroxyurea, Hydroxycarbamide
- **DRUG:** Valproic acid
- **DRUG:** 6-Mercaptopurine (6-MP)

## Key facts

- **NCT ID:** NCT06199557
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2025-11-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199557, "A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06199557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*